Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 6Inflammatory Bowel Diseases 3Colonic Polyps 3Colonic Neoplasms 3Surgical Wound Infection 2Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Sarcoma 1Rectal Neoplasms 1Polyps 1Ovarian Neoplasms 1Opioid-Induced Constipation 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Intestinal Neoplasms 1Gastrointestinal Hemorrhage 1Diverticulitis 1Cancer Pain 1Adenoma 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Polyethylene Glycols × Clear all
NCT01287585 2019-09-06

ADI-PEG 20

Polaris Group

Phase 3 Completed
636 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02101593 2016-03-04

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Polaris Group

Phase 1 Completed
8 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡